VRCA, US92511W2070

Verrica Pharmaceuticals stock presents new YCANTH data ahead of conferences

Published on 10/06/2026 at 12:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Verrica Pharmaceuticals stock closed at USD 4.31 on October 5, 2026, while new YCANTH data showed 60.1 percent clearance by Day 84. Two conference dates follow.

VRCA, US92511W2070, Illustration mit AI erstellt.

Verrica Pharmaceuticals stock (ISIN US92511W2070) closed at USD 4.31 on Nasdaq on October 5, 2026, down 1.60 percent from the prior close. The company is taking new YCANTH and VP-315 clinical analyses to dermatology conferences beginning October 8, according to GlobeNewswire on September 30, 2026.

YCANTH data show a wide gap

The pooled post-hoc analysis of the CAMP-1 and CAMP-2 Phase 3 trials found a complete-clearance hazard ratio of 4.06 for VP-102 versus vehicle. By Day 84, cumulative complete clearance reached 60.1 percent with VP-102, compared with 19.9 percent with vehicle, according to GlobeNewswire.

The result matters commercially because YCANTH is already approved for molluscum contagiosum in adults and children age 2 and older, while VP-315 remains an investigational program for basal cell carcinoma. The September 30 release describes the VP-315 presentation as an exploratory analysis of untreated, non-target lesions.

Revenue remains tied to execution

Verrica reported USD 5.86 million of revenue and a GAAP net loss of USD 13.15 million for the quarter ended June 30, 2026, according to Markets Insider. Revenue was USD 12.7 million in the year-earlier quarter, showing why product demand and pipeline progress remain important to the investment case.

MarketBeat lists a Hold consensus based on 5 analysts, with an average price target of USD 12.67, a low target of USD 9.00 and a high target of USD 17.00. Against the October 5 price of USD 4.31, the stock lies 66.0 percent below the average target, while Markets Insider reported on September 30 that Lake Street maintained a Buy rating and a USD 9.00 target.

Verrica stock stays near its yearly low

At USD 4.31, Verrica stock stood USD 1.03 above its 52-week low of USD 3.28 and USD 5.51 below its 52-week high of USD 9.82 on October 5, 2026. The session range was USD 4.25 to USD 4.54, volume was 34,346 shares and market capitalization was USD 74.1 million.

The next valuation test is operational: the company must convert YCANTH's approved status and the new clinical data into sustained demand while funding its development pipeline. The scheduled conference appearances provide the next dated checkpoints for that process.